Literature DB >> 32989500

Cytotoxic and anti-angiogenic effects of zoledronic acid in DU-145 and PC-3 prostate cancer cell lines.

Cenk Gokalp1.   

Abstract

This study aims to investigate the apoptotic and anti-angiogenic effect of Zoledronic acid on hormone-refractory prostate cancer cell lines. XTT cell proliferation assay used to assess cytotoxicity. Caspase 3/7 activity and DNA fragmentation were measured to verify apoptosis. Angiogenic cytokine profiles investigated using the human angiogenesis antibody array I. Administration of Zoledronic acid on PC-3 and DU-145 prostate cancer cell lines resulted in increased cytotoxicity and apoptosis with a time- and dose-related manner. Also, the administration of Zoledronic acid significantly reduced several angiogenic cytokine productions in PC-3 and DU-145 cell lines. Zoledronic acid successfully induced apoptosis and reduced various angiogenic cytokine production in hormone-refractory prostate cancer cell lines. Novel treatment protocols may be developed in the future with chemotherapeutic combinations for the treatment of prostate cancer.

Entities:  

Keywords:  Angiogenesis; DU-145; PC-3; Prostate cancer; Zoledronic acid

Mesh:

Substances:

Year:  2020        PMID: 32989500     DOI: 10.1007/s11033-020-05840-6

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  2 in total

1.  Sonic hedgehog signaling is associated with resistance to zoledronic acid in CD133high/CD44high prostate cancer stem cells.

Authors:  Eda Acikgoz; Gunel Mukhtarova; Araz Alpay; Cigir Biray Avci; Bakiye Goker Bagca; Gulperi Oktem
Journal:  Mol Biol Rep       Date:  2021-05-04       Impact factor: 2.316

2.  High affinity zoledronate-based metal complex nanocrystals to potentially treat osteolytic metastases.

Authors:  Gabriel Quiñones Vélez; Lesly Carmona-Sarabia; Alondra A Rivera Raíces; Tony Hu; Esther A Peterson-Peguero; Vilmalí López-Mejías
Journal:  Mater Adv       Date:  2022-02-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.